Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского» Минздрава России. 119991, Россия, Москва, Кропоткинский пер., д. 23 marachevm@gmail.com
Список исп. литературыСкрыть список 1. Sibitz I et al. ICD-10 or DSM-IV? Anhedonia, fatigue and depressed mood as screening symptoms for diagnosing a current depressive episode in physically ill patients in general hospital. J Affect Dis 2010; 126 (1): 245–51. 2. Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR* D study. J Affect Dis 2015; 172: 96–102. 3. Olson TR, Presniak MD, MacGregor MW. Reevaluating positive affect in the Center for Epidemiologic Studies-Depression scale. Psychiatry Res 2010; 178 (3): 545–9. 4. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19 (1): 34–40. 5. Kampermann L, Nestoriuc Y, Shedden-Mora MC. Physicians’ beliefs about placebo and nocebo effects in antidepressants–an online survey among German practitioners. PloS Оne 2017; 12 (5): e0178719. 6. Read J et al. Beliefs of people taking antidepressants about the causes of their own depression. J Affect Dis 2015; 174: 150–6. 7. Chen JA et al. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry 2011; 72 (12): 1669–76. 8. Sinyor M et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses 2010. 9. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR* D) trial: a review. Canadian J Psychiatry 2010; 55 (3): 126–35. 10. Demyttenaere K, Donneau AF, Albert A et al. What is important in being cured from depression? Discordance between physicians and patients (1). J Affect Dis 2015; 174: 390–6. 11. Collins PY, Patel V, Joestl SS et al. Grand challenges in global mental health. Nature 2011; 475 (7354): 27–30. DOI: 10.1038/475027a. PubMed PMID: 21734685; PubMed Central PMCID: PMC3173804. 12. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9 (2): 87–98. PubMed PMID: 17007486. 13. Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64 (12): 1465–75. PubMed PMID: 14728109. 14. Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996; 274 (5288): 740–3. PubMed PMID: 8966556. 15. Stewart WF, Ricci JA, Chee E et al. Cost of lost productive work time among US workers with depression. JAMA 2003; 289 (23): 3135–44. Erratum in: JAMA 2003; 290 (16): 2218. PubMed PMID: 12813119. 16. Judd LL et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Dis 1998; 50 (2): 97–108. 17. Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59 (11): 608–19. PubMed PMID: 9862607. 18. Geschwind N, Nicolson NA, Peeters F et al. Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. Eur Neuropsychopharmacol 2011; 21 (3): 241–7. DOI: 10.1016/j.euroneuro.2010.11.004. Epub 2010 Dec 13. PubMed PMID: 21146375. 19. Uher R et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Med 2012; 42 (5): 967–80. 20. Kennedy SH, Avedisova A, Giménez-Montesinos N et al; Agomelatine Study Group. A placebo-controlled study of three agomelatine doseregimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder. Eur Neuropsychopharmacol 2014; 24 (4): 553–63. DOI: 10.1016/j.euroneuro.2014.01.006. PubMed PMID: 24530273. 21. Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry 2017; 44: 1–8. DOI: 10.1016/j.eurpsy.2017.02.485. PubMed PMID: 28535406. 22. Castle D, Hopwood M, Crawford A. Raising the profile of affective blunting in general practice. Australian & New Zealand J Psychiatry 2015; 49: 106–7. 23. Zimmerman M et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry 2006; 163 (1): 148–50. 24. Gorwood P et al. Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive tests. Eur Neuropsycho-pharmacol 2014; 24 (10): 1630–40. 25. Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015; 28 (6): 418–23. DOI: 10.1097/YCO.0000000000000198. Review. PubMed PMID: 26382168. 26. Englisch S, Jung HS, Lewien A et al. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study. J Clin Psychopharmacol 2016; 36 (6): 597–607. PubMed PMID: 27805978.